P2B001 is an extended-release or ER formulation, meaning that the medication is formulated so that it is released slowly over time. It contains low doses of pramipexole (0.6 mg) and rasagiline (0.75 mg). Both compounds are approved therapies for Parkinson’s — marketed as Mirapex (pramipexole) and Azilect (rasagiline). The low doses used in P2B001 are not currently available on the market.
New Phase 3 Trial Data Back P2B001 as The... - Cure Parkinson's
New Phase 3 Trial Data Back P2B001 as Therapy for Early Parkinson’s
Written by
Farooqji
To view profiles and participate in discussions please or .
Read more about...
1 Reply
•
what is is considered early early Parkinson
Not what you're looking for?
You may also like...
First Patient Dosed in Phase 3 Trial of Buntanetap for Early Parkinson's
https://parkinsonsnewstoday.com/news/first-early-stage-parkinsons-patient-dosed-phase-3-trial-buntan
Bayer reports positive early data for Parkinson’s cell therapy
clinical trial....
B 1 therapy for Parkinson’s
B 1 taken sublingually and followed that for 2 doses of 50mg, after receiving recommendations that...
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease
globenewswire.com/news-release/2024/05/09/2878650/0/en/Annovis-Announces-Unblinding-of-the-Buntaneta
Anyone participating in the Buntanetap Phase 3 trial?
com/cure-parkinsons/posts/148436640/annovis-bio-announces-first-patient-dosed-in-phase-3-trial-in-pa